SafeBoosC: Safeguarding the brain of our smallest children – an investigator-initiated randomised, blinded, multinational, phase II  feasibility clinical trial on  near-infrared spectroscopy monitoring combined with defined treatment guidelines versus standard monitoring and treatment as usual in premature infants. 

SafeBoosC is a multicentre phase II clinical trial with 13 participating clinical centres. SafeBoosc is taking place in the Cork University Maternity Hospital with Consultant Neonatologist and Neonatal Brain Research Group member Dr Eugene Dempsey as the national coordinator and Principle Investigator. Dr Dempsey has extensive research experience and is currently the Chief Investigator of an FP7 funded project ‘The HIP Trial’.

The primary objective of the SafeBoosC trial is to examine if it is possible to stabilise the cerebral oxygenation of extremely preterm infants during the first 72 hours of life through the application of cerebral NIRS oximetry and implementation of an rStO₂-specific clinical treatment guideline. We hypothesise that by using the specified treatment guideline to respond to cerebral monitoring readings outside the target range, we would reduce the burden of hypo- and hyperoxia and consequently reduce brain injury. Overall 150 preterm infants will be enrolled into this trial.

For further information please click here -  
SafeBoosC